Thanks to visit codestin.com
Credit goes to cardiooncologyjournal.biomedcentral.com

Skip to main content
BMC is moving to Springer Nature Link. Visit this journal in its new home.

Articles

Page 1 of 8

  1. Children, adolescents, and young adults with cancer (referred to as CAYAs) are at risk of long-term health complications, with cardiovascular disease (CVD) being a major concern. In addition, sociodemographic ...

    Authors: John Södling, Jakob Hytting, Panagiotis Mallios, Entela Bollano, Madeleine Johansson, Kenny A. Rodriguez-Wallberg, Elham Hedayati, Patric Karlström, Per Sundbom, Narsis Kiani, Robin Keskisärkkä, Martin Singull and Laila Hubbert
    Citation: Cardio-Oncology 2025 11:92
    Content type: Research Published on:

  2. Although rare, cardiac metastases are increasingly reported in oncology. Surgery may be an option for selected patients, but is often not feasible due to high postoperative morbidity. Radiotherapy therefore em...

    Authors: Olivier Cravéreau, A. Stefani, I. Buchheit, T. Loustaud, A. Grimon, W. Gehin, N. Martz, M. Bruand, C. Simon, V. Marchesi, C. De Chillou, JM. Sellal and JC. Faivre
    Citation: Cardio-Oncology 2025 11:91
    Content type: Case Report Published on:

  3. Anthracyclines can cause dose-dependent cardiotoxicity that may be irreversible. To minimize cardiotoxic effects, substituting doxorubicin for liposomal doxorubicin (LD) has been explored as a cardioprotective...

    Authors: Germano Dallegrave Cavalli, Jose P. Lopez-Lopez, Frances Caringal Carandang, Ainsley Johnstone, Sara Scampoli, Ruqqiyah Rana, Pedro Teixeira Meireles, Jo-Anne Petropoulos, Christopher Hillis, Amaris Balitsky, Jenica Upshaw and Darryl P. Leong
    Citation: Cardio-Oncology 2025 11:90
    Content type: Research Published on:

  4. Treatment of breast cancer by chemotherapy or radiotherapy exposes the patient to the risk of cardiotoxicity, which can be assessed pre-therapeutically using scores such as the Heart Failure Association and Inter...

    Authors: Chris Nadège Nganou-Gnindjio, Etienne Atenguena Okobalemba, Loic Alban Tasong, Aude Marlène Zende, Jules Thierry Elong, Patricia Tumtchou, Berthe Esson Mapoko, Junie Annick Metogo, Felix Essiben and Bâ Hamadou
    Citation: Cardio-Oncology 2025 11:89
    Content type: Research Published on:

  5. Childhood cancer survivors (CCS) often experience cancer treatment-related cardiotoxicity, leading to reduced cardiorespiratory fitness (CRF), an integrated marker of cardiovascular, respiratory, and musculosk...

    Authors: Olga H. Toro-Salazar, Linda S. Pescatello, May Ling Mah, Carolyn Wilhelm, Andrea D. Orsey, Tiffany Berthod, Maua H. Mosha, Michael Brimacombe, Tongyao Fan, Corbinian Wanner, Michelle Slawinski and Kan N. Hor
    Citation: Cardio-Oncology 2025 11:88
    Content type: Research Published on:

  6. Anthracycline-induced cardiomyopathy is a leading cause of morbidity and mortality in survivors of childhood cancer. The mitochondrion is a key mediator of the cytotoxic effects of anthracycline treatment and ...

    Authors: Patrick J. Trainor, Purnima Singh, Xuexia Wang, Noha Sharafeldin, Liting Zhou, Lindsey Hageman, Saro H. Armenian, Jill P. Ginsberg, Douglas S. Hawkins, Frank G. Keller, Melissa M. Hudson, Joseph P. Neglia, Wendy Landier and Smita Bhatia
    Citation: Cardio-Oncology 2025 11:87
    Content type: Research Published on:

  7. Early identification of cardiac involvement in oncology patients is critical but challenging. To date, no validated protocol integrates dedicated cardiac magnetic resonance imaging (CMR) within routine whole-b...

    Authors: Yaqiong Zhou, Hua Lin, Chuan Huang, Yuanwei Xu, Yangjie Li, Chunchao Xia, Qing Zhang, Yuchi Han, Xiaohong Ou and Yucheng Chen
    Citation: Cardio-Oncology 2025 11:86
    Content type: Correspondence Published on:

  8. Cardiovascular disease (CVD) and cancer are the two leading causes of death in the US. Preclinical models support a direct effect of cardiovascular disease (CVD) on accelerated cancer growth and spread. Our ob...

    Authors: Kevin T. Nead, Allen M. Haas, Jing Zhao, Ting Xiong, Chad Tang, Sharon H. Giordan and Nicholas J. Leeper
    Citation: Cardio-Oncology 2025 11:85
    Content type: Research Published on:

  9. Immune checkpoint inhibitors (ICIs) have become the standard for treating various cancers. Nevertheless, their use may lead to significant cardiovascular immune-related adverse events (CV irAEs).

    Authors: Moaad Slieman, Ophir Freund, Galit Aviram, Haim Shmilovich, Zach Rozenbaum, Moran Gvili Perelman, Lior Zornitzki, Dana Viskin, Anna Rozenfeld Hemed, Shafik Khoury, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Joseph Carver and Michal Laufer-Perl
    Citation: Cardio-Oncology 2025 11:84
    Content type: Research Published on:

  10. Cancer therapy-related cardiac dysfunction (CTRCD) is recognized complication of antineoplastic therapies, and is particularly associated with anthracyclines. Treatment revolves around heart failure management...

    Authors: Isabel G. Scalia, Ramzi Ibrahim, Mahmoud Abdelnabi, Hoang Nhat Pham, Juan M. Farina, Milagros Pereyra Pietri, Kwan S. Lee, Balaji K. Tamarappoo, Reza Arsanjani and Chadi Ayoub
    Citation: Cardio-Oncology 2025 11:83
    Content type: Research Published on:

  11. Fruquintinib is a highly selective tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which play a critical role in angiogenesis and tumor growth. As a nov...

    Authors: Ahmad Nouri, Ameer Awashra, Dawoud Hamdan, Islam Rajab, Abdalhakim Shubietah, Yahya Ismail and Anan Abu Rmilah
    Citation: Cardio-Oncology 2025 11:82
    Content type: Research Published on:

  12. Cardiac Amyloidosis (CA) remains highly underdiagnosed, especially among patients with causes of increased ventricular wall thickness, such as aortic stenosis (AS). The prevalence of CA throughout the spectrum...

    Authors: Fabian Voß, Elric Zweck, Jean Marc Haurand, Jafer Haschemi, Christian Jung, Tobias Zeus, Kathrin Klein, Ralf Westenfeld, Stephan Angendohr, Roland Fenk, Roman Pfister, Maximilian Spieker, Malte Kelm, Amin Polzin and Daniel Scheiber
    Citation: Cardio-Oncology 2025 11:81
    Content type: Correspondence Published on:

  13. Carcinoid Heart Disease (CHD) primarily affects the right heart valves, while left heart involvement is rare and often associated with a patent foramen ovale (PFO). Early identification of a PFO in CHD can be ...

    Authors: Nuno Cotrim, Ricardo Carvalheiro, Bárbara Teixeira, Tânia Mano, Lídia de Sousa, Mariana Saraiva and Vítor Martins
    Citation: Cardio-Oncology 2025 11:80
    Content type: Case Report Published on:

  14. SGLT2i exerts several cardiometabolic benefits in heart failure with reduced and preserved ejection fraction through the systemic reduction of insulin, visceral fat, chemokines and growth factors involved in c...

    Authors: A. Greco, V. Quagliariello, G. Rizzo, A. Tedeschi, S. Schirinzi, A. Turco, M. Galiazzo, M. Acquaro, M. De Amicis, C. Klersy, S. Ghio, L. Perrone, A. Paccone, G. Uccello, M. L. Canale, S. Oliva…
    Citation: Cardio-Oncology 2025 11:79
    Content type: Research Published on:

  15. Adult survivors of haematological malignancies are at increased risk of long-term cardiovascular sequelae. Several echocardiographic metrics have been tested to detect subclinical myocardial dysfunction before...

    Authors: Massimiliano Camilli, Federico Ballacci, Priscilla Lamendola, Marcello Viscovo, Giulia Tamburrini, Lorenzo Tinti, Ilaria Torre, Ludovica Amore, Stefan Hohaus, Filippo Crea, Gaetano Antonio Lanza, Francesco Burzotta, Giorgio Minotti and Antonella Lombardo
    Citation: Cardio-Oncology 2025 11:78
    Content type: Research Published on:

  16. Patients with primary central nervous system lymphoma (PCNSL) often require high-dose methotrexate (HD-MTX)-based regimens for effective disease control. However, the coexistence of heart failure with a reduce...

    Authors: Vanessa M. Barrionuevo-Villacis and Mauricio X. Davila
    Citation: Cardio-Oncology 2025 11:77
    Content type: Review Published on:

  18. Cardiotoxicity is a significant challenge associated with common first-line breast cancer (BC) anti-neoplastic (CTx) treatments including anthracyclines (AC) and targeted immunotherapies, such as anti-Her-2 th...

    Authors: Natalia Do Couto, Mary Hidde, Georgios Grigoriadis, Rodney Sparapani, Matt Durand, Michael Widlansky, Courtney Jankowski, Madeline Berendt, Bethany Canales, Sarah Golus, Laura E. Norwood Toro, Purushottam Laud, Amanda Kong, Kent Hoskins, David Lewandowski, Shane A. Phillips…
    Citation: Cardio-Oncology 2025 11:75
    Content type: Methodology Published on:

  19. Anti-HER2 receptor monoclonal antibodies like trastuzumab are the mainstay of treatment in HER2-positive breast cancer but can result in cancer therapy-related cardiac dysfunction (CTRCD). Guidelines recommend...

    Authors: Le Huang, Pratyusha Manthena, Malcolm Su, Alvin Chandra and Navid Sadeghi
    Citation: Cardio-Oncology 2025 11:74
    Content type: Research Published on:

  20. The cancer therapy–related cardiac dysfunction (CTRCD) induced by anthracycline could involve the whole heart. However, the overall changes of strain parameters, including the atrial and right heart strains, m...

    Authors: Shuo Qiu, Yuxin Zhang, Ying Hou, Songhao Chen, Huihui Yu, Han Li, Lianbi Zhao, Xiaofang Zhang, Xi Zhang, Jiahan Liu, Changyang Xing, Yunyou Duan and Lijun Yuan
    Citation: Cardio-Oncology 2025 11:73
    Content type: Research Published on:

  22. Advances in cancer therapeutics have significantly improved patient survival; however, cardiotoxic effects—including arrhythmias—have emerged as a growing clinical concern. This expert opinion, developed by th...

    Authors: Kalliopi Keramida, Ourania Kariki, Eleni Angelopoulou, Ioannis Kalafatis, Christos Lafaras, Konstantinos P. Letsas, Helena Michalopoulou, Athanasios Saplaouras, Konstantinos Tampakis, Dorothea Tsekoura and George Andrikopoulos
    Citation: Cardio-Oncology 2025 11:71
    Content type: Review Published on:

  23. Neoplasms are a major cause of mortality globally, where early diagnosis is essential for improving outcomes. Current diagnostic methods are often invasive, expensive, and inaccessible in resource-limited sett...

    Authors: Juan Miguel Lopez Alcaraz, Wilhelm Haverkamp and Nils Strodthoff
    Citation: Cardio-Oncology 2025 11:70
    Content type: Research Published on:

  24. A cardio-oncology multidisciplinary team is essential for the successful delivery of patient-centred care. The roles of oncologists, haematologists, and cardiologists have been clearly articulated in literatur...

    Authors: Joshua D. Bennetts, Trent D. Williams, Craig J. Beavers, Heather N. Moore, Cameron Robson, Thomas Warner, Susan Dent, Aaron L. Sverdlov and Doan T.M. Ngo
    Citation: Cardio-Oncology 2025 11:69
    Content type: Review Published on:

  25. Tyrosine kinase inhibitor (TKI) therapy improves the overall survival of patients with chronic myeloid leukemia (CML). However, the risk of vascular adverse events (VAEs) in these patients is reported to be hi...

    Authors: Naoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomonori Nakazato, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Katsuhiro Miura and Tatsuya Kawaguchi
    Citation: Cardio-Oncology 2025 11:68
    Content type: Research Published on:

  26. Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD),...

    Authors: Abdelrahman Ali, Maximillian Bourdillon, Hyeon-Ju Ryoo Ali, Juhee Song, Efstratios Koutroumpakis, Poonam Jewani, Shaden Khalaf, Ihab Hamzeh, Salil Kumar, Nicolas L. Palaskas, Jean-Bernard Durand and Cezar Iliescu
    Citation: Cardio-Oncology 2025 11:67
    Content type: Research Published on:

  28. Anthracycline-induced cardiotoxicity is a significant concern for breast cancer patients undergoing treatment, often leading to chronic cardiovascular complications and reduced long-term survival. The study ai...

    Authors: Runyu Liu, Cong Fan, Xiaoling Liu, Mengmeng Li, Yuan Zhang and Mei Zhang
    Citation: Cardio-Oncology 2025 11:65
    Content type: Review Published on:

  29. The risk of drug-induced corrected QT interval (QTc) prolongation is an important consideration in clinical decision-making for patients with hormone receptor-positive/human epidermal growth factor receptor 2-...

    Authors: Susan Dent, Heather Moore, Michael Fradley, Chloe Grace Rose, Stella Stergiopoulos, Connie Chen, Benjamin Li and Avirup Guha
    Citation: Cardio-Oncology 2025 11:64
    Content type: Research Published on:

  30. Cardiovascular adverse events (CVAE) are clinically relevant side effects during treatment with the proteasome inhibitor carfilzomib. We investigated the predictive value of cardiac biomarkers for onset of CVA...

    Authors: Lisa B. Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-S. Raab, Christoph Mann, Christian S. Michel, Hans Christian Reinhardt, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny…
    Citation: Cardio-Oncology 2025 11:63
    Content type: Research Published on:

  31. Neoadjuvant chemotherapy-immunotherapy is the new standard of care for high-risk early-stage triple negative breast cancer (TNBC). As anthracyclines, pembrolizumab, and radiotherapy may each contribute to an i...

    Authors: Jean Philippe Nesseler, Katrina D. Silos, Olivia Peony, Asneh Singh, Patrick Belen, Mitchell R. Kamrava, Julie K. Jang, Stephen L. Shiao, Alan C. Kwan, Cody Ramin, Raymond H. Mak, Andriana P. Nikolova and Katelyn M. Atkins
    Citation: Cardio-Oncology 2025 11:62
    Content type: Research Published on:

  32. Stem Cell Transplantation (SCT) is a cornerstone therapy in managing several malignant and benign hematological conditions. Atrial fibrillation/atrial flutter (AF) are commonly encountered in patients receivin...

    Authors: Raja Zaghlol, Elena Deych, Nina Manian, Ahmed Altibi and Joshua D. Mitchell
    Citation: Cardio-Oncology 2025 11:61
    Content type: Research Published on:

  33. Chimeric Antigen Receptor (CAR) T-cell therapy (CAR-T) has emerged as a promising treatment for specific hematological malignancies. While some studies suggest an association between CAR-T and atrial fibrillat...

    Authors: Nischit Baral, Nabin R. Karki, Daniel A. Ladin, Raja Zaghlol, Mahmoud Ibrahim, Alexander Rabadi, Tarec K. Elajami, Olivia Mechanic, Arvind Kunadi and Joshua D. Mitchell
    Citation: Cardio-Oncology 2025 11:60
    Content type: Research Published on:

  34. Pegylated liposomal doxorubicin (PLD) and bevacizumab are commonly used to treat platinum-resistant ovarian cancer. While both agents are associated with cardiovascular toxicities, their combined impact on car...

    Authors: Christopher W. Hoeger, Arrush Choudhary, Andrea Nathalie Rosas Diaz, Theresa Pinto, Sarah Smalec, Charles Doladille, Rishi Wadhera, Meghan Shea, Sumanth Khadke, Joe-Elie Salem, Sarju Ganatra and Aarti Asnani
    Citation: Cardio-Oncology 2025 11:59
    Content type: Research Published on:

  35. Primary cardiac sarcomas (PCS) are rare, aggressive malignancies with poor prognosis and limited evidence guiding optimal management. We aimed to evaluate clinical and histopathological parameters in a single-...

    Authors: Anton Burkhard-Meier, Dorit Di Gioia, Vindi Jurinovic, Michael Hoberger, Sinan E. Güler, Michael Völkl, Stefanie Corradini, Aurélie V. Gaasch, Annabel H. S. Alig, Thomas Knösel, Christian Hagl, Christian Schneider, Wulf Sienel, Wolfgang G. Kunz, Caspar Burkhard-Meier, Michael von Bergwelt-Baildon…
    Citation: Cardio-Oncology 2025 11:58
    Content type: Research Published on:

  37. Cardiovascular toxicity concerns have limited the use of anthracyclines and trastuzumab among breast cancer patients with cardiovascular disease (CVD) but evidence on real-world prescribing patterns is scarce....

    Authors: Helena Carreira, Helen Strongman, Maria Feychting, Laila Hubbert, Elham Hedayati, Patrick Bidulka, Anthony Matthews and Krishnan Bhaskaran
    Citation: Cardio-Oncology 2025 11:56
    Content type: Research Published on:

  38. Childhood cancer survivors (CCS) often develop late complications after their primary disease is cured. Cardiovascular disease is one of the most frequent and serious complications that significantly affects p...

    Authors: Yuri Okazoe-Hirakawa, Kimikazu Yakushijin, Keiji Kurata, Sakuya Matsumoto, Hiroya Ichikawa, Rina Sakai, Taku Nose, Shiro Kimbara, Yoshiaki Nagatani, Taiji Koyama, Yumiko Inui, Yohei Funakoshi, Naomi Kiyota, Mitsuhiro Ito, Keiko Hatazawa, Hidekazu Tanaka…
    Citation: Cardio-Oncology 2025 11:55
    Content type: Research Published on:

  39. Breast cancer survivors treated with radiotherapy (RT) face elevated long-term risk of cardiovascular complications. Double product (DP), the product of systolic blood pressure and heart rate, reflects myocard...

    Authors: Juan Manuel Garzon-Dangond, Maria F. Gomez Ardila, Eduardo Tellez Garcia, Andres E. Daryanani, Prema P. Peethambaram, Lori A. Thicke, Daniela L. Stan and Hector R. Villarraga
    Citation: Cardio-Oncology 2025 11:54
    Content type: Research Published on:

  40. Anthracycline-induced cardiotoxicity (ACT) is a significant concern for cancer survivors, while genetic basis of ACT remains unclear. This study employs a murine genetic reference population (GRP) of BXD recom...

    Authors: Buyan-Ochir Orgil, Akhilesh K. Bajpai, Neely Alberson, Morgan Lander, Batsaikhan Enkhzul, Hugo R. Martinez, Jeffrey A. Towbin, Lu Lu and Enkhsaikhan Purevjav
    Citation: Cardio-Oncology 2025 11:53
    Content type: Research Published on:

  41. Non-cancer deaths are now becoming a significant threat to the health of cancer patients. Death from atherosclerosis is linked to cancer due to the side effects of treatment and its pathogenesis. However, guid...

    Authors: Ramez M. Odat, Sakhr Alshwayyat, Dang Nguyen, Tala Abdulsalam Alshwayyat, Hanan M. Qasem, Hritvik Jain, Hamdah Hanifa, Osama Aloudat, John C. Lin, Wilfred Ngwa, Margaret E. G. Thompson and Amer Harky
    Citation: Cardio-Oncology 2025 11:52
    Content type: Research Published on:

  42. Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF asso...

    Authors: Patrick A. Kwaah, Samuel A. Mensah, Emmanuel A. Agyemang, Joseph S. Kekrebesi, Daniil Katkov, Abraham Carboo, Grace Appah, Hamza A. Rashid and Jennifer M. Kwan
    Citation: Cardio-Oncology 2025 11:51
    Content type: Research Published on:

  43. The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on reducing cardiovascular events in different subgroups of diabetic patients are under investigation. The current systematic review and meta-an...

    Authors: Tara Reshadmanesh, Reza Mohebi, Amir Hossein Behnoush, Azadeh Reshadmanesh, Amirmohammad Khalaji, Mitra Norouzi, Elmira Javanmardi, Reza Pishdad, S. Reza Jafarzadeh, Elina Ghondaghsaz and Sandra Chaparro
    Citation: Cardio-Oncology 2025 11:50
    Content type: Review Published on:

  44. Global longitudinal strain (GLS) is an important prognostic indicator for predicting heart failure and cancer therapy-related cardiac dysfunction (CTRCD). Although access to GLS measurement has increased acros...

    Authors: Tagayasu Anzai, Kenji Hirata, Ken Kato and Kohsuke Kudo
    Citation: Cardio-Oncology 2025 11:49
    Content type: Research Published on:

    The Correction to this article has been published in Cardio-Oncology 2025 11:57

  45. Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment...

    Authors: Johanne D. Lyhne, Vibeke B. Hansen, Lone D. Vestergaard, Susanne E. Hosbond, Martin Busk, Mayooran Gnanaganesh, Else Maae, Birgitte M. Havelund, Torben F. Hansen, Signe Timm, Lars H. Jensen and Mads D. Lyhne
    Citation: Cardio-Oncology 2025 11:48
    Content type: Research Published on:

  46. Anthracycline-induced cardiomyopathy is a well-established adverse consequence in childhood cancer survivors. Altered mRNA expression in the peripheral blood has been found at the level of genes and pathways a...

    Authors: Purnima Singh, David K. Crossman, Changde Cheng, Patrick J. Trainor, Noha Sharafeldin, Xuexia Wang, Liting Zhou, Lindsey Hageman, Saro H. Armenian, Frank M. Balis, Douglas S. Hawkins, Frank G. Keller, Melissa M. Hudson, Joseph P. Neglia, Jill P. Ginsberg, Wendy Landier…
    Citation: Cardio-Oncology 2025 11:47
    Content type: Research Published on:

  47. This study aimed to investigate the impact of the proportion of hematologic malignancy patients in hospitals on the prognosis of chronic lymphocytic leukemia (CLL) patients undergoing cardiac surgery. Perioper...

    Authors: Meizhen Yi, Lanxin Hu, Jifang Zhou, Yali Ge, Cunhua Su and Fan Yang
    Citation: Cardio-Oncology 2025 11:46
    Content type: Research Published on:

  48. Cardiac involvement is the primary driver of death in systemic light chain (AL) amyloidosis. However, the early prediction of cardiac death risk in AL amyloidosis remains insufficient.

    Authors: Naidong Pang, Ying Tian, Hongjie Chi, Xiaohong Fu, Xin Li, Shuyu Wang, Feifei Pan, Dongying Wang, Lin Xu, Jingyi Luo, Aijun Liu and XingPeng Liu
    Citation: Cardio-Oncology 2025 11:45
    Content type: Research Published on:

  49. Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protect...

    Authors: Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar and Jacob K. Kresovich
    Citation: Cardio-Oncology 2025 11:44
    Content type: Research Published on:

  50. The emerging discipline of cardio-oncology addresses the cardiovascular complications associated with cancer therapies. In sub-Saharan Africa (SSA), where both cardiovascular disease (CVD) and cancer-related m...

    Authors: Princess Afia Nkrumah-Boateng, Adam Ben-Jaafar, Allswell Naa Adjeley Boye, Pearl Ohenewaa Tenkorang, Toufik Abdul-Rahman and Wireko Andrew Awuah
    Citation: Cardio-Oncology 2025 11:43
    Content type: Correspondence Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact
    Journal Impact Factor: 3.2 (2024)    
    5-year Journal Impact Factor: 3.3 (2024)    
    Source Normalized Impact per Paper (SNIP): 0.799 (2024)    
    SCImago Journal Rank (SJR): 0.886 (2024)

    Speed 
    Submission to first editorial decision (median days): 13
    Submission to acceptance (median days): 100

    Usage 2024
    Downloads: 253,129
    Altmetric mentions: 271

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us